Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.
Aged
Biopsy
Cause of Death
Disease Progression
Exercise Tolerance
Female
Humans
Idiopathic Pulmonary Fibrosis
/ diagnosis
Incidence
Japan
/ epidemiology
Lung
/ pathology
Male
Middle Aged
Predictive Value of Tests
Prognosis
Pulmonary Diffusing Capacity
Retrospective Studies
Time Factors
Vital Capacity
Walk Test
acute exacerbation
idiopathic pulmonary fibrosis
risk factors
surgical lung biopsy
usual interstitial pneumonia
Journal
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
ISSN: 2532-179X
Titre abrégé: Sarcoidosis Vasc Diffuse Lung Dis
Pays: Italy
ID NLM: 9610928
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
02
2018
accepted:
19
09
2018
entrez:
2
6
2020
pubmed:
1
1
2019
medline:
1
7
2020
Statut:
ppublish
Résumé
In 2016, the diagnostic criteria for the acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) were revised. However, there have been published few clinical reports on AE-IPF published using the new criteria. The aim of this study was to investigate the incidence of, risk factors for, and mortality due to newly defined AE. Moreover, differences between triggered AE and idiopathic AE were investigated. The retrospective study was conducted including all IPF patients diagnosed with surgically-proven usual interstitial pneumonia through multi-disciplinary discussion between January 2006 and December 2015. Data were retrieved from a clinical chart review. A total of 107 patients with newly diagnosed 107 IPF patients were included. The cumulative incidence of initial AE were 9.6% at 1 year, 16.8% at 2 years, 23.9% at 3 years, and 37.3% at 4 years after diagnosis. Three risk factors for AE-IPF development were identified: 1) the minimum peripheral ozygen saturation level of ≤88% during the 6-minute walk test at the time of diagnosis; 2) forced vital capacity (FVC) decreasing by ≥10% in 1 year; and 3) diffusion capacity of the lungs for carbon monoxide (DLco) decreasing by ≥15% in 1 year. There were no significant differences in background (excluding C-reactive protein), survival and treatment between patients with triggered AE and those with idiopathic AE. The 6-minute walk test and an annual decline in FVC and DLco were predictive factors for AE incidence. The causes of AE-IPF did not affect the prognosis or treatment options in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
In 2016, the diagnostic criteria for the acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) were revised. However, there have been published few clinical reports on AE-IPF published using the new criteria. The aim of this study was to investigate the incidence of, risk factors for, and mortality due to newly defined AE. Moreover, differences between triggered AE and idiopathic AE were investigated.
METHODS
METHODS
The retrospective study was conducted including all IPF patients diagnosed with surgically-proven usual interstitial pneumonia through multi-disciplinary discussion between January 2006 and December 2015. Data were retrieved from a clinical chart review.
RESULTS
RESULTS
A total of 107 patients with newly diagnosed 107 IPF patients were included. The cumulative incidence of initial AE were 9.6% at 1 year, 16.8% at 2 years, 23.9% at 3 years, and 37.3% at 4 years after diagnosis. Three risk factors for AE-IPF development were identified: 1) the minimum peripheral ozygen saturation level of ≤88% during the 6-minute walk test at the time of diagnosis; 2) forced vital capacity (FVC) decreasing by ≥10% in 1 year; and 3) diffusion capacity of the lungs for carbon monoxide (DLco) decreasing by ≥15% in 1 year. There were no significant differences in background (excluding C-reactive protein), survival and treatment between patients with triggered AE and those with idiopathic AE.
CONCLUSIONS
CONCLUSIONS
The 6-minute walk test and an annual decline in FVC and DLco were predictive factors for AE incidence. The causes of AE-IPF did not affect the prognosis or treatment options in clinical practice.
Identifiants
pubmed: 32476935
doi: 10.36141/svdld.v36i1.7117
pii: SVDLD-36-39
pmc: PMC7247113
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39-46Informations de copyright
Copyright: © 2019.
Références
Chest. 1996 Aug;110(2):325-32
pubmed: 8697828
Respir Investig. 2015 Nov;53(6):271-8
pubmed: 26521104
Eur Respir J. 2006 Jan;27(1):143-50
pubmed: 16387947
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1162-1171
pubmed: 28657784
Eur Respir J. 2011 Feb;37(2):356-63
pubmed: 20595144
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64
pubmed: 10673212
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75
pubmed: 27299520
COPD. 2008 Apr;5(2):117-24
pubmed: 18415810
Respirology. 2017 Oct;22(7):1363-1370
pubmed: 28508494
Am J Respir Crit Care Med. 2003 Nov 1;168(9):1084-90
pubmed: 12917227
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Eur Respir J. 2010 Apr;35(4):821-9
pubmed: 19996196
J Clin Diagn Res. 2017 Apr;11(4):OC34-OC38
pubmed: 28571188
Eur Respir J. 2016 Apr;47(4):1189-97
pubmed: 26917616
Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(2):103-10
pubmed: 21319592
Respir Res. 2013 Jul 13;14:73
pubmed: 23848435
Radiology. 2013 Mar;266(3):936-44
pubmed: 23220902
Lung. 2014 Feb;192(1):141-9
pubmed: 24221341
Respir Med. 2014 Jul;108(7):1031-9
pubmed: 24835074
Lancet Respir Med. 2018 Feb;6(2):138-153
pubmed: 29154106